RedHill Biopharma Ltd.
RedHill Biopharma Ltd. (RDHL) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
rdhl · stock forecast · 10 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 10 Wall Street analysts in the past 3 months
Buy
10 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $1.02
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $1.03 | ↑ 1.02% |
1-day model range: $1.03–$1.04. Peak: $1.04 (+1.02%).
Long-Term Stock Price Prediction
Annual stock price forecast · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $1 | -50.0% |
| 2028 | $0 | -62.5% |
| 2029 | $0 | -67.2% |
| 2030 | $0 | -69.2% |
| 2031 | — | -70.2% |
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · RDHL · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2021-09-15 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2021-08-31 | Cantor Fitzgerald | Maintains | Overweight→Overweight |
| 2021-05-28 | WBB Securities | Downgrade ↓ | Strong Buy→Buy |
| 2021-05-18 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2020-09-11 | BTIG | Maintains | Buy→Buy |
| 2020-03-05 | H.C. Wainwright | Maintains | Buy→Buy |
| 2019-07-12 | WBB Securities | Upgrade ↑ | Buy→Strong Buy |
| 2019-03-12 | WBB Securities | Maintains | Speculative Buy→Buy |
| 2018-06-25 | Ladenburg Thalmann | Maintains | Buy→Buy |
| 2018-01-26 | Nomura | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on RedHill Biopharma Ltd. (RDHL) stock. Of the recent 14 rating actions, 1 were upgrades and 1 were downgrades. 10 analysts currently cover RDHL.
Analyst Recommendation Trends
RDHL analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$68M
↑ 226.9% YoY
Revenue Next Year
$9M
↓ 86.8% YoY
EPS This Year
$-70.00
EPS Next Year
$-80.00
↑ 14.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast RDHL EPS of $-70.00 for the current fiscal year, based on estimates from 13 analysts. The RDHL revenue forecast is $68M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The RDHL stock forecast is supported by two independent data sources: analyst consensus ratings from 10 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus RDHL price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The RDHL short-term stock prediction for tomorrow is $1.03 (+1.02%). The RDHL stock price prediction for 2027 estimates an average of $1. The RDHL stock prediction for 2030 projects a range of $0–$0.
RedHill Biopharma Ltd. trades on NASDAQ under the ticker RDHL. The RDHL stock outlook for 2027 is broadly positive, supported by a Buy consensus among 100% of covering analysts.
Frequently asked questions
RDHL forecast · 8 questionsAccording to 10 Wall Street analysts, the average 12-month RDHL price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $1.02.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.